Sangamo Therapeutics (Sangamo Therapeutics) Debt-to-Equity

: 0.46 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Sangamo Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.6 Mil. Sangamo Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $33.5 Mil. Sangamo Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $82.9 Mil. Sangamo Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.46.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sangamo Therapeutics's Debt-to-Equity or its related term are showing as below:

SGMO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.12 Max: 0.46
Current: 0.46

During the past 13 years, the highest Debt-to-Equity Ratio of Sangamo Therapeutics was 0.46. The lowest was 0.03. And the median was 0.12.

SGMO's Debt-to-Equity is ranked worse than
73.83% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs SGMO: 0.46

Sangamo Therapeutics Debt-to-Equity Historical Data

The historical data trend for Sangamo Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.10

0.08

0.13

0.15

0.46

Sangamo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.15	0.11	0.16	0.26	0.46

Competitive Comparison

For the Biotechnology subindustry, Sangamo Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangamo Therapeutics Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's Debt-to-Equity falls into.

Sangamo Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sangamo Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.589	+	33.515)	/	82.887
	=	0.46

Sangamo Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.589	+	33.515)	/	82.887
	=	0.46

Sangamo Therapeutics (NAS:SGMO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sangamo Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GBY:Germany

Address

7000 Marina Boulevard, Brisbane, CA, USA, 94005

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Executives

Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney	director	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow	officer: SVP-Chief Development Officer	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker	director
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby	officer: SVP, Gen. Counsel & Secretary	7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb	officer: EVP & General Counsel	5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot	officer: SVP, Chief Scientific Officer	7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott	officer: SVP, Head of Development	7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier	officer: EVP, Technical Operations	7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung	officer: EVP Chief Business Officer	7000 MARINA BLVD, BRISBANE CA 94005